⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672213 | 1.00 | — | — | |
| SCHEMBL27471960 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL2183314 | 0.97 | — | — | |
| SCHEMBL209221 | 0.81 | — | — | |
| SCHEMBL275234 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL25334514 | 0.77 | — | — | |
| Ammonia Solution, Strong SCHEMBL4647423 | 0.77 | SLC7A5 (0.42) | — | |
| Ammonia Solution, Strong SCHEMBL4647428 | 0.77 | — | — | |
| SCHEMBL4648068 | 0.77 | — | — | |
| Bicarbonate SCHEMBL10985561 | 0.77 | SLC7A5 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 793 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-54041874-A | — | — | None | — | — | JP | disclosed |
| US-20260146073-A1 | T CELL RECEPTORS TARGETING MUTATED CDKN2A | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4748856-A2 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SELF-DRIVING CHIMERIC ANTIGEN RECEPTORS | Lentigen Technology, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4747362-A2 | METHODS FOR RAPID MANUFACTURE OF ENGINEERED T CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | Kyverna Therapeutics, Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| EP-4743578-A2 | THERAPY FOR ALPHA-1 ANTITRYPSIN DEFICIENCY | Precigen, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12630650-B2 | Engineered IgA antibodies and methods of use | TIGATX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12630802-B2 | Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2026-05-19 | — | — | US | disclosed |
| US-12630637-B2 | Antigen-binding proteins and related methods of use | GRITSTONE BIO, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260130938-A1 | NOVEL RECEPTORS FOR TRANSCRIPTION REGULATION | ARSENAL BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4739396-A1 | HUMANIZED 40H3 ANTIBODY | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20060199769-A1 | ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-09-07 | — | — | US | disclosed |
| EP-1448593-A4 | ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF | CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM INC (US) | 2006-08-30 | — | — | EP | disclosed |
| US-20050271587-A1 | Alpha-fetoprotein peptides and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2005-12-08 | — | — | US | disclosed |
| WO-2003044040-A9 | ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF | CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM INC (US) | 2005-01-06 | — | — | WO | disclosed |
| US-6818741-B2 | PREVENTION OF BREAST CANCER | CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM, INC. | 2004-11-16 | — | — | US | disclosed |
| EP-1448593-A2 | ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF | CLF Medical Technology Acceleration Program, Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030170752-A1 | Alpha-fetoprotein peptides and uses thereof | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-09-11 | — | — | US | disclosed |
| WO-2003044040-A2 | ALPHA-FETOPROTEIN PEPTIDES AND USES THEREOF | CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| WO-2003044041-A2 | ALPHA-FETOPROTEIN PEPTIDES AND USES FOR IMAGING | CLF MEDICAL TECHNOLOGY ACCELERATION PROGRAM, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| JP-S5441874-A | NOVEL 2-SUBSTITUTED IMIDAZOLE DERIVATIVE | SUMITOMO CHEM CO LTD | 1979-04-03 | — | — | JP | disclosed |